Company Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases.
It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.
Clene Inc. is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2012 |
| Industry | Packaged Foods |
| Sector | Consumer Staples |
| Employees | 76 |
| CEO | Robert Etherington |
Contact Details
Address: 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121 United States | |
| Phone | 801 676 9695 |
| Website | clene.com |
Stock Details
| Ticker Symbol | CLNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1822791 |
| CUSIP Number | 185634102 |
| ISIN Number | US1856342019 |
| Employer ID | 85-2828339 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Etherington MBA | Chief Executive Officer, President and Director |
| Morgan R. Brown CPA, M.B.A. | Chief Financial Officer |
| Mark G. Mortenson ESQ. | Chief Science Officer |
| Jerry Miraglia J.D. | General Counsel and Corporate Secretary |
| Mary Anne Mcneil | Head of Human Resources |
| Michael T. Hotchkin | Chief Development Officer |
| Dr. Benjamin M. Greenberg M.D., M.H.S. | Head of Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 3, 2026 | 144 | Filing |
| Jan 13, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 424B5 | Filing |
| Dec 30, 2025 | 25-NSE | Filing |
| Dec 5, 2025 | 144 | Filing |